查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984221

抗發炎治療市場：2026-2032年全球市場預測（依治療分類、作用機制、給藥途徑、適應症、通路及最終用戶分類）

Anti-Inflammatory Therapeutics Market by Therapeutic Class, Mechanism Of Action, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗發炎藥物市場價值將達到 221.6 億美元，到 2026 年將成長至 231.9 億美元，到 2032 年將達到 338.5 億美元，複合年成長率為 6.23%。

主要市場統計數據
基準年 2025 221.6億美元
預計年份：2026年 231.9億美元
預測年份 2032 338.5億美元
複合年成長率 (%) 6.23%

該分析整合了臨床獎勵、相關人員和決策者的策略重點，揭示了現代抗發炎療法的現狀。

發炎性疾病的治療模式呈現出快速的科學進步、臨床範式的轉變以及日益複雜的商業性環境等特徵。分子生物學和免疫學的進步拓展了臨床醫生可選擇的治療方案，而患者的期望和支付方的嚴格審查則凸顯了相對安全性、長期療效和真實世界療效的重要性。本文獎勵了當前發炎性疾病的治療環境，整合了影響藥物研發和商業化的臨床因素、監管影響以及相關人員。

從科學突破、適應性監管途徑和商業性壓力三個方面，對治療創新和獲取的動態進行綜合觀點，從根本上改變治療創新和獲取的動態。

抗發炎領域的蓬勃發展得益於科學、監管和商業性領域諸多轉折點的匯聚，這些轉折點正在重塑治療方法的發現、開發和應用方式。近年來，治療策略已從廣泛的免疫抑制轉向針對特定發炎路徑的調節，這重新定義了人們對療效、安全性和長期疾病管理的預期。同時，監管路徑也在不斷發展，以適應新的治療方法和適應性開發方法，促使申辦方在專案設計的早期階段就將監管策略納入考量。

詳細分析 2025 年美國關稅調整將如何影響整個治療領域產品組合的供應鏈韌性、製造策略和產品供應。

關稅政策和貿易趨勢將對醫藥原料和成品的供應及成本結構產生微妙但顯著的影響。 2025年美國關稅調整為供應鏈規劃、籌資策略和國際採購決策引入了新的變數。製造商和經銷商正在透過重新評估供應商所在地、選擇替代製造地以及重新評估庫存政策來應對這些變化，以維持供應的連續性並保護利潤率結構。

基於全面細分的洞察，將治療領域、作用機制、給藥途徑、分銷管道、適應症和最終用戶趨勢與實際開發和商業化挑戰聯繫起來。

精細化的市場區隔觀點揭示了不同治療領域、作用機制、給藥途徑、分銷管道、適應症和終端用戶所面臨的獨特策略挑戰，這些挑戰在產品開發和商業化過程中都呈現出獨特的機會和限制因素。按治療領域分類，市場涵蓋生物製藥和糖皮質激素，以及緩解疾病抗風濕藥、 Janus激酶抑製劑、非類固醇消炎劑和磷酸二酯酶抑制劑，每種藥物在臨床證據、生產複雜性和上市後安全性監測方面都提出了不同的要求。依作用機制分類，治療方法靶向Cyclooxygenase通路、白細胞介素訊號通路、 Janus激酶級聯反應、磷酸二酯酶和腫瘤壞死因子（TNF），這種機制的多樣性要求採用個體化的生物標記策略和差異化的臨床終點。

針對美洲、歐洲、中東、非洲和亞太地區，協調監管多樣性、償還模式和基礎設施現實的區域性策略考量。

區域趨勢對監管合作、報銷途徑和商業性實施有顯著影響，每個區域都有其獨特的臨床模式和業務重點。在美洲，醫療保健系統涵蓋了從高度私有化模式到公共保險主導模式的各種類型，導致處方集、就醫時間和患者支持計劃要求等方面存在差異。該區域的臨床實踐模式和指南採納情況會影響保險公司和醫療服務提供者對療效比較的預期以及對證據標準的要求。

主要企業如何將科學差異化、策略聯盟和生命週期策略結合，以最佳化其治療產品線並向支付方證明其價值？

主要企業之間的競爭體現在科學差異化、策略夥伴關係和產品組合最佳化等。產業領導者優先考慮作用機制明確的實證標標靶治療，並投資於生物製藥和小分子藥物，這些藥物與傳統的頻譜藥物相比，安全性更高，特異性更強。跨領域合作與授權授權十分普遍，各公司力求利用外部創新來補充自身能力，縮短臨床試驗週期，並降低後期研發風險。

為了確保產品順利上市和持續獲得治療方法，高階主管需要採取切實可行的、優先的行動，協調研發、生產、市場進入和商業化團隊。

行業領導者應採取綜合方法，使早期科學篩選與後續市場進入和商業性需求保持一致。這種方法應包括從計畫設計的最初階段就納入支付方和衛生經濟學的見解，確保臨床試驗終點和健康結果指標相關人員報銷利害關係人而言可靠。同時，投資生產柔軟性和地理多元化將確保供應連續性，並降低貿易中斷帶來的風險。

透過高度透明的調查方法，結合專家訪談、有針對性的二級文獻綜述和橫斷面分析，對臨床、監管和營運方面檢驗。

本執行摘要的研究基礎整合了定性訪談、有針對性的二手文獻綜述以及對監管和政策變化的結構化分析。訪談對象包括臨床意見領袖、供應鏈主管、市場進入專家和治療領域專家，涵蓋了多方相關人員的觀點。二級資訊來源包括同儕審查的臨床文獻、監管指導文件以及闡述機制特定證據和供應考慮的技術白皮書。

這個結論總結了治療創新、證據一致性和實施在發炎性疾病治療中如何全面決定長期成功和對患者的影響。

總之，精準的機制標靶化、適應性監管預期以及對可證實的實際療效日益成長的需求，正在改變抗發炎療法領域。這些因素為研發者、支付者和醫療服務提供者帶來了機會和責任，促使他們在循證實踐、供應鏈韌性以及以患者為中心的醫療模式方面開展合作。治療差異化越來越需要分子設計、劑型和市場進入策略的協調一致，從而確保治療方法的廣泛應用和患者的永續效益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按治療分類分類的抗發炎治療藥物市場

  • 生物製藥
  • 皮質類固醇
  • 緩解疾病抗風濕藥物
  • Janus激酶抑制劑
  • 非類固醇消炎劑
  • 磷酸二酯酶抑制劑

第9章：按作用機轉分類的抗發炎藥物市場

  • Cyclooxygenase抑制劑
  • 白細胞介素抑制劑
  • Janus激酶抑制劑
  • 磷酸二酯酶抑制劑
  • 腫瘤壞死因子抑制劑

第10章：抗發炎治療藥物市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下
  • 外用
    • 奶油
    • 凝膠
    • 軟膏

第11章：抗發炎治療藥物市場：依適應症分類

  • 氣喘和呼吸系統疾病
  • 痛風
  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 骨關節炎
  • 銀屑病
  • 類風濕性關節炎

第12章：抗發炎治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：抗發炎治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院
  • 專業醫療中心

第14章：抗發炎治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 抗發炎治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 抗發炎治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國抗發炎治療藥物市場

第18章：中國抗發炎藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC, Amgen Inc.
  • Bioventus
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring Pharmaceuticals
  • Flexion Therapeutics, Inc
  • GlaxoSmithKline
  • Johnson & Johnson
  • La Roche AG
  • Merck & CO., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-5C6F41F5B03B

The Anti-Inflammatory Therapeutics Market was valued at USD 22.16 billion in 2025 and is projected to grow to USD 23.19 billion in 2026, with a CAGR of 6.23%, reaching USD 33.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.16 billion
Estimated Year [2026] USD 23.19 billion
Forecast Year [2032] USD 33.85 billion
CAGR (%) 6.23%

Framing the contemporary anti-inflammatory therapeutics landscape by synthesizing clinical innovation, stakeholder incentives, and strategic priorities for decision-makers

The therapeutic landscape for inflammatory disorders is characterized by rapid scientific progress, shifting clinical paradigms, and intensifying commercial complexity. Advances in molecular biology and immunology have expanded the toolbox available to clinicians, while patient expectations and payer scrutiny have elevated the importance of comparative safety, long-term outcomes, and real-world effectiveness. This introduction frames the current environment by synthesizing clinical drivers, regulatory influences, and stakeholder incentives that collectively shape development and commercialization pathways.

Translational breakthroughs have created opportunities across a spectrum of modalities, from targeted cytokine inhibitors to orally administered small molecules that modulate intracellular signaling. At the same time, traditional anti-inflammatory agents remain central to acute symptom control and perioperative management, reinforcing the need for integrated care models. By combining clinical insight with market-oriented perspectives, this section sets the groundwork for subsequent analysis, clarifying how therapeutic differentiation, delivery format, and distribution strategy influence adoption and lifecycle planning.

The objective of this executive summary is to present a balanced, evidence-informed narrative that supports strategic prioritization. It emphasizes where therapeutic innovation aligns with unmet clinical need, how shifting treatment paradigms affect stakeholder behavior, and what programmatic considerations should guide investment decisions. In short, the introduction is intended to orient readers to the principal forces shaping therapeutic development and access in the anti-inflammatory domain.

An integrated view of scientific breakthroughs, adaptive regulatory pathways, and commercial pressures that are fundamentally altering treatment innovation and access dynamics

Momentum in the anti-inflammatory space is driven by convergent scientific, regulatory, and commercial inflection points that are reshaping how therapies are discovered, developed, and adopted. Recent years have seen a pronounced pivot from broad immunosuppression toward targeted modulation of discrete inflammatory pathways, which has recalibrated expectations for efficacy, safety, and long-term disease control. Concurrently, regulatory pathways have evolved to accommodate novel modalities and adaptive development approaches, prompting sponsors to embed regulatory strategy early in program design.

Commercially, payers and health systems are leveraging real-world evidence and value-based contracting to distinguish treatments that demonstrate durable benefit and cost offsets. This pressure has encouraged manufacturers to align trial endpoints more closely with patient-centered outcomes and health economic measures. Additionally, technological innovations in drug delivery and telemedicine have broadened access pathways, enabling novel channel strategies and patient-centric support services that can influence adherence and persistence.

The cumulative effect is a more complex but opportunity-rich ecosystem in which therapeutic differentiation is multi-dimensional. Scientific advances permit more precise targeting of disease biology, regulatory adaptations encourage innovative development frameworks, and commercial stakeholders increasingly demand demonstrable value. As a result, organizations that integrate clinical evidence generation, payer engagement, and agile commercialization planning will be best positioned to navigate the evolving terrain.

A nuanced analysis of how 2025 United States tariff adjustments are influencing supply chain resilience, manufacturing strategy, and product availability across therapeutic portfolios

Tariff policies and trade dynamics can exert a subtle yet material influence on the availability and cost structure of pharmaceutical inputs and finished products. Changes to United States tariffs in 2025 have introduced new variables for supply chain planning, procurement strategy, and international sourcing decisions. Manufacturers and distributors have responded by reassessing supplier footprints, qualifying alternate manufacturing sites, and re-evaluating inventory policies to maintain continuity of supply and to protect margin structures.

These adjustments have been particularly relevant for parenteral products and biologics, where cold-chain logistics and contract manufacturing relationships are tightly integrated with production timelines. In some instances, firms have accelerated vertical integration or capacity investments to mitigate exposure to cross-border cost fluctuations. Concurrently, emphasis on nearshoring and regional manufacturing hubs has increased, as organizations seek to reduce geopolitical risk and to shorten lead times for critical therapeutic agents.

Beyond manufacturing, payers and health systems may see indirect effects as procurement practices adapt to changed cost bases. Providers are reassessing formularies and group purchasing arrangements to preserve affordability while ensuring clinical adequacy. Overall, the tariff landscape underscores the importance of resilient supply chains, scenario-based financial modeling, and proactive stakeholder communication to sustain product availability and to preserve patient access.

Comprehensive segmentation-driven insights that map therapeutic class, mechanism, delivery, channels, indications, and end-user dynamics to practical development and commercialization imperatives

A granular segmentation lens reveals distinct strategic imperatives across therapeutic class, mechanism of action, route of administration, distribution channel, indication, and end user, each presenting unique opportunities and constraints for product development and commercialization. Based on Therapeutic Class, the market spans Biologics and Corticosteroids as well as Disease Modifying Antirheumatic Drugs, Janus Kinase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, and Phosphodiesterase Inhibitors, with each class posing different demands for clinical evidence, manufacturing complexity, and post-marketing safety surveillance. Based on Mechanism Of Action, therapies target Cyclooxygenase pathways, Interleukin signaling, Janus Kinase cascades, Phosphodiesterase enzymes, and Tumor Necrosis Factor, and the mechanistic diversity necessitates tailored biomarker strategies and differentiated clinical endpoints.

Based on Route Of Administration, therapeutic delivery choices include Oral, Parenteral, and Topical formats, where parenteral administration divides further into Intramuscular, Intravenous, and Subcutaneous approaches and topical treatments are delivered via Creams, Gels, and Ointments; these delivery distinctions influence adherence profiles, healthcare utilization patterns, and the complexity of manufacturing and distribution. Based on Distribution Channel, therapies move through Hospital Pharmacy networks, Online Pharmacy platforms, and Retail Pharmacy outlets, and each channel carries different requirements for cold-chain, patient support, and reimbursement interactions. Based on Indication, clinical targets include Asthma And Pulmonary Diseases, Gout, Inflammatory Bowel Disease, Osteoarthritis, Psoriasis, and Rheumatoid Arthritis, with Inflammatory Bowel Disease further categorized into Crohn's Disease and Ulcerative Colitis; indication-specific natural history affects trial design, responder definitions, and long-term safety monitoring. Based on End User, settings span Clinic, Home Care, Hospital, and Specialty Center, with each care environment influencing point-of-care delivery, patient education needs, and support service integration.

Taken together, this segmentation framework highlights that therapeutic success is contingent on aligning molecule attributes with the operational realities of manufacturing, channels, and clinical care settings. Strategic planners should consider how a therapy's class and mechanism guide evidence generation, how administration route shapes patient experience and adherence, and how distribution and end-user dynamics will affect access, uptake, and lifecycle management. In practice, cross-functional alignment between R&D, commercial, manufacturing, and market access teams is essential to translate segment-specific requirements into executable development and launch plans.

Region-specific strategic considerations that reconcile regulatory diversity, reimbursement paradigms, and infrastructure realities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a strong influence on regulatory interactions, reimbursement pathways, and commercial execution, with each geography presenting distinctive clinical paradigms and operational priorities. In the Americas, healthcare systems vary from highly privatized to public payer-dominated models, driving heterogeneity in formulary decisions, access timelines, and patient support program requirements. Clinical practice patterns and guideline adoption in this region influence comparative effectiveness expectations and the evidence standards that payers and providers demand.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant variation in reimbursement capacity and health technology assessment methodologies. Manufacturers must navigate diverse pricing environments, local guideline adoption, and varying degrees of infrastructure for specialty care, which affects launch sequencing and patient access strategies. Capacity constraints in certain markets can also influence distribution and cold-chain investments.

In Asia-Pacific, rapid adoption of innovative therapies is often balanced against affordability pressures and evolving regulatory frameworks that can accelerate approval for therapies addressing high unmet need. Local manufacturing partnerships and regional clinical development programs are frequently used to support access and meet regulatory expectations. Across all regions, cross-border supply chain resilience, pharmacovigilance harmonization, and culturally tailored patient support models are critical for ensuring sustainable access and maximizing clinical impact.

How leading firms are combining scientific differentiation, strategic partnerships, and lifecycle tactics to optimize therapeutic pipelines and demonstrate payer-aligned value

Competitive behavior among leading companies reflects a mix of scientific differentiation, strategic partnerships, and portfolio optimization. Industry players are prioritizing targeted therapies with clear mechanistic rationales and have been investing in biologics and small molecules that offer improved safety and specificity compared with older broad-spectrum agents. Cross-sector collaborations and licensing arrangements are widespread as firms seek to complement internal capabilities with external innovation, accelerate time to clinic, and de-risk late-stage development.

Manufacturers are also placing an increased emphasis on life-cycle management tactics, including reformulations, novel delivery systems, and indication expansion strategies to extend therapeutic relevance. In parallel, companies are investing in real-world evidence generation, patient engagement platforms, and outcomes-based contracting models to demonstrate value to payers and health systems. Organizationally, there is a trend toward integrated teams that combine clinical development, market access, and commercial functions to ensure that evidence packages align with payer expectations and provider needs.

These competitive dynamics underscore the importance of agility, data-driven decision-making, and strategic partnering. Enterprises that can efficiently translate mechanistic insight into differentiated products, while simultaneously building robust evidence generation and access strategies, are positioned to navigate both clinical and commercial complexities.

Practical and prioritized actions for executives to align R&D, manufacturing, market access, and commercial teams to ensure resilient launches and sustained therapeutic adoption

Industry leaders should adopt an integrated approach that aligns early-stage scientific choices with downstream access and commercial requirements. Initiatives should include embedding payer and health economics input at the earliest program design stages to ensure that trial endpoints and health outcome measures will be credible to reimbursement stakeholders. Simultaneously, investments in manufacturing flexibility and geographic diversification will safeguard supply continuity and reduce exposure to trade disruptions.

Commercial plans must prioritize patient-centric delivery models and digital support mechanisms that improve adherence and enable remote monitoring of therapeutic response. Strategic partnerships with clinical networks, specialty pharmacies, and technology vendors can accelerate patient access and reduce the burden on traditional distribution channels. Moreover, life-cycle management should be treated as a continuous process that encompasses reformulation, delivery innovation, and indication sequencing to sustain clinical relevance.

Finally, organizations should institutionalize agile governance frameworks that facilitate cross-functional decision-making, rapid evidence integration, and scenario-based planning. These practical steps will enable companies to translate clinical innovation into durable commercial success while maintaining alignment with payer expectations and patient needs.

Transparent methodology combining expert interviews, targeted secondary review, and cross-sectional analytic techniques to validate clinical, regulatory, and operational insights

The research underpinning this executive summary synthesizes primary qualitative interviews, targeted secondary literature review, and structured analysis of regulatory and policy changes. Key informant interviews included clinical thought leaders, supply chain executives, market access specialists, and therapeutic area experts to capture multi-stakeholder perspectives. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers that contextualize mechanism-specific evidence and delivery considerations.

Analytical methods combined thematic synthesis with cross-sectional mapping of segmentation attributes to identify where clinical innovation intersects with operational constraints. Evidence validation steps included triangulation of interview findings with published clinical data and supply chain disclosures. Limitations and uncertainties are acknowledged, and sensitivity to evolving regulatory and trade dynamics was incorporated through scenario-based analysis. The methodology emphasizes transparency in source attribution and reproducibility of analytic choices to support informed decision-making.

Conclusion synthesizing how therapeutic innovation, evidence alignment, and operational execution collectively determine long-term success and patient impact in inflammatory diseases

In summary, the anti-inflammatory therapeutics landscape is being reshaped by precise mechanistic targeting, adaptive regulatory expectations, and heightened demands for demonstrable real-world value. These forces create both opportunities and responsibilities for developers, payers, and providers to collaborate on evidence generation, supply chain resilience, and patient-centered care models. Therapeutic differentiation increasingly requires alignment across molecule design, delivery format, and market access strategies to ensure uptake and sustainable patient benefit.

Moving forward, stakeholders who integrate clinical evidence with pragmatic operational planning will be best positioned to deliver meaningful outcomes while navigating commercial complexity. Sustained success depends not only on scientific innovation but also on the ability to orchestrate manufacturing, regulatory, and payer engagements in a coordinated fashion. The conclusion reinforces that strategic foresight, cross-functional execution, and a relentless focus on patient outcomes are the foundational elements for enduring impact in the anti-inflammatory domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Inflammatory Therapeutics Market, by Therapeutic Class

  • 8.1. Biologics
  • 8.2. Corticosteroids
  • 8.3. Disease Modifying Antirheumatic Drugs
  • 8.4. Janus Kinase Inhibitors
  • 8.5. Nonsteroidal Anti-Inflammatory Drugs
  • 8.6. Phosphodiesterase Inhibitors

9. Anti-Inflammatory Therapeutics Market, by Mechanism Of Action

  • 9.1. Cyclooxygenase Inhibitors
  • 9.2. Interleukin Inhibitors
  • 9.3. Janus Kinase Inhibitors
  • 9.4. Phosphodiesterase Inhibitors
  • 9.5. Tumor Necrosis Factor Inhibitors

10. Anti-Inflammatory Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Gels
    • 10.3.3. Ointments

11. Anti-Inflammatory Therapeutics Market, by Indication

  • 11.1. Asthma And Pulmonary Diseases
  • 11.2. Gout
  • 11.3. Inflammatory Bowel Disease
    • 11.3.1. Crohn's Disease
    • 11.3.2. Ulcerative Colitis
  • 11.4. Osteoarthritis
  • 11.5. Psoriasis
  • 11.6. Rheumatoid Arthritis

12. Anti-Inflammatory Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Anti-Inflammatory Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Care
  • 13.3. Hospital
  • 13.4. Specialty Center

14. Anti-Inflammatory Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-Inflammatory Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-Inflammatory Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Anti-Inflammatory Therapeutics Market

18. China Anti-Inflammatory Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC, Amgen Inc.
  • 19.8. Bioventus
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Eli Lilly and Company
  • 19.11. F. Hoffmann-La Roche Ltd
  • 19.12. Ferring Pharmaceuticals
  • 19.13. Flexion Therapeutics, Inc
  • 19.14. GlaxoSmithKline
  • 19.15. Johnson & Johnson
  • 19.16. La Roche AG
  • 19.17. Merck & CO., Inc.
  • 19.18. Novartis AG
  • 19.19. Pfizer Inc.
  • 19.20. Sanofi S.A.
  • 19.21. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)